Debt Financing Update

RNS Number : 8406W
Life Science REIT PLC
23 August 2022
 

23 August 2022

LEI 2 13800RG7JNX7K8F7525

A green sign with white text Description automatically generated with medium confidence

Life Science REIT plc

("Life Science REIT" or the "Company")

 

Debt Financing Update

Drawdown to advance asset management plans

Life Science REIT (AIM: LABS), the real estate investment trust focused on UK life science properties, announces that it has completed a second drawdown from its existing £150m debt facility with HSBC totalling £37.2m.

The drawdown is secured against the Company's acquisitions at Herbrand Street in London, Lumen House near Oxford and the Merrifield Centre in Cambridge.

The current debt facility was initially announced on 30 March 2022 and comprises a £75m three year term loan and a £75m revolving credit facility.  The Company has secured additional protection against potential future interest rate rises through capping the SONIA rate at 2.0% until 31 March 2025 on the full amount of the term loan.

In total, £48.7m remains available in the revolving credit facility for future use.

The proceeds from this second drawdown from the debt facility will be used to progress the development and repositioning of assets within the existing portfolio as flagship life science properties following bespoke plans capitalising on their compelling locations. The anticipated works include the fitout of laboratory space at Cambourne Business Park near Cambridge and at Rolling Stock Yard in London's Knowledge Quarter.

Simon Farnsworth, Managing Director of Ironstone Asset Management Ltd, the Company's Investment Adviser, said:

"We are pleased to report further positive progress in developing a high quality and diverse portfolio of life science properties in the key national centres of this critically important industry. The drawdown of this capital enables us to progress these properties to the next stage of their individual asset management plans and we look forward to providing further updates as the repositioning of these assets continues to evolve."

Enquiries:

Link Company Matters Limited - Company Secretary

 

labs_cosec@linkgroup.co.uk

 

 

 

Ironstone Asset Management - Investment Adviser

 

Simon Farnsworth

via Buchanan below

 

 

Panmure Gordon (UK) Limited - Nominated Adviser and Joint Corporate Broker

+44 20 7886 2500

Atholl Tweedie / Alex Collins / Philip Shields / Chloe Ponsonby


 

 

Jefferies International Limited - Joint Corporate Broker

+44 20 7029 8000

Tom Yeadon / Andrew Morris / Oliver Nott / Harry Randall 

 


 

G10 Capital Limited - AIFM

+44 20 7397 5450

Verity Morgan-Jones / Paul Cowland

 

 

 



Buchanan - Financial PR

+44 20 7466 5000

Mark Court / Henry Wilson / Verity Parker 


LifeSciencereit@buchanan.uk.com


 

Notes to editors

Life Science REIT plc is a property business focused solely on the UK's growing life science sector, specifically targeting opportunities in the "Golden Triangle" research and development hubs of Oxford, Cambridge and London St Pancras. The Company's intention is to become the property provider of choice for life science companies in the UK, whilst enabling shareholders to gain exposure to a specific growth sector.

The objective of the Company's investment policy is focused on capital growth, whilst also providing a growing level of income, by investing primarily in a diversified portfolio of properties that are leased, or intended to be leased, to occupiers operating in the life science sector in the UK.

Life Science REIT joined the AIM market of the London Stock Exchange on 19 November 2021, having raised £350 million in its IPO. Its shares trade under the ticker LABS.

Further information is available at  https://lifesciencereit.co.uk

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UPDEANPAADKAEFA
UK 100

Latest directors dealings